Ning Cui

Title: Ning Cui - Innovator in Anti-Schizophrenia Drug Development

Introduction

Ning Cui is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds aimed at treating schizophrenia. His innovative work has the potential to improve the lives of many individuals affected by this mental health condition.

Latest Patents

Ning Cui holds a patent for benzoisothiazole compounds and methods of treating schizophrenia. The patent discloses compounds that exhibit a strong affinity for dopamine D receptors and 5-HT receptors. These compounds have shown promising results in improving symptoms of schizophrenia in both apomorphine model and MK-801 model mice. The oral absorption of these compounds is good, with high safety and minimal side effects, indicating their developmental value as new anti-neurotic disease drugs. The compounds are characterized by a general formula (I), including geometric isomers, free alkalies, salts, hydrates, or solvates thereof.

Career Highlights

Ning Cui is affiliated with the Shanghai Institute of Pharmaceutical Industry, where he conducts his research and development activities. His work is recognized for its potential impact on the pharmaceutical industry and mental health treatment.

Collaborations

Ning Cui collaborates with notable colleagues, including Jianqi Li and Xiaowen Chen, who contribute to his research efforts and advancements in the field.

Conclusion

Ning Cui's innovative work in developing benzoisothiazole compounds represents a significant advancement in the treatment of schizophrenia. His contributions to pharmaceutical sciences highlight the importance of research in improving mental health therapies.